{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:30:51Z","timestamp":1782901851412,"version":"3.54.5"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>The chemotherapy response score (CRS) proposed by Bohm and colleagues in 2015 has been validated as a reproducible method for determining histopathologic response of tubo-ovarian carcinoma to neoadjuvant chemotherapy and stratifies tumor response into 3 groups: CRS1 is defined as minimal\/no response, CRS2 as moderate response, and CRS3 as marked response. Although described as a 3-tiered system, it essentially works as a 2-tiered system (CRS1\/CRS2 vs. CRS3) for assessing prognosis. Here, we analyzed the prognostic value of CRS in a large cohort of tubo-ovarian carcinomas at a tertiary care center and evaluated the potential for Ki-67 labeling index on post-neoadjuvant chemotherapy samples to provide additional prognostic information. We included 170 patients with tubo-ovarian carcinoma treated with neoadjuvant chemotherapy followed by interval debulking surgery. We determined CRS for each case by reviewing slides from the interval debulking surgery resection specimen and calculated progression-free survival and overall survival. For each case with residual disease (CRS1 and CRS2, n=123, 72%), we also performed Ki-67 antibody staining and determined both average and highest Ki-67 labeling index. Consistent with prior studies, patients in our cohort with CRS1 and CRS2 showed significantly shorter progression-free survival and overall survival compared with CRS3. Further, in the subset of cases with CRS1 and CRS2, Ki-67 labeling index was predictive of OS at multiple cutoff points. An average Ki-67 labeling index of 20% (log rank test <jats:italic toggle=\"yes\">P<\/jats:italic>-value: 0.0004) or a highest Ki-67 labeling index of 50% (log rank test <jats:italic toggle=\"yes\">P<\/jats:italic>-value: 0.0002) could provide a practically useful cutoff. Multivariable cox proportional hazard model showed worse overall survival with both, average Ki-67 &gt;20% (hazard ratios: 2.02, <jats:italic toggle=\"yes\">P<\/jats:italic>-value: 0.00422, confidence interval: 1.25\u20133.28) and highest Ki-67 &gt;50% (hazard ratios: 1.88, <jats:italic toggle=\"yes\">P<\/jats:italic>-value: 0.0205, confidence interval: 1.1\u20133.2). We propose adding Ki-67 labeling index to CRS to provide additional prognostic separation between patients with CRS1 and CRS2.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000706","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T17:00:21Z","timestamp":1599411621000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy"],"prefix":"10.1097","volume":"40","author":[{"given":"Michelle","family":"Heayn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren B.","family":"Skvarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Olawaiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesmary","family":"Modugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Elishaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"issue":"suppl 2","key":"R1-20250802","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"Berek","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"suppl 1","key":"R3-20250802","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0923-7534(20)31477-0","article-title":"Surgery during chemotherapy and at relapse of ovarian cancer","volume":"10","author":"Berek","year":"1999","journal-title":"Ann Oncol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(15)01052-1","article-title":"Primary chemotherapy versus primary surgery for ovarian cancer\u2014Authors\u2019 reply","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur J Cancer"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"Bohm","year":"2015","journal-title":"J Clin Oncol"},{"key":"R9-20250802","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2018-000092","article-title":"Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated chemotherapy response score (CRS) results","author":"Bohm","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PGP.0000000000000307","article-title":"The chemotherapy response score (CRS): interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in tuboovarian high-grade serous carcinoma","volume":"36","author":"Said","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fonc.2019.00778","article-title":"Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: the prognostic role of omental and ovarian residual disease","volume":"9","author":"Santoro","year":"2019","journal-title":"Front Oncol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/IGC.0000000000001366","article-title":"Prognostic value of pathologic chemotherapy response score in patients with ovarian cancer after neoadjuvant chemotherapy","volume":"28","author":"Michaan","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/his.13399","article-title":"The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma","volume":"72","author":"Singh","year":"2018","journal-title":"Histopathology"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2018.08.042","article-title":"Prognostic implications of histological tumor regression (Bohm\u2019s score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma","volume":"151","author":"Rajkumar","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.3802\/jgo.2017.28.e73","article-title":"External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/IGC.0000000000000945","article-title":"Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma","volume":"27","author":"Coghlan","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","article-title":"Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"28","author":"McCluggage","year":"2015","journal-title":"Mod Pathol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecologic oncology"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 2","key":"R24-20250802","first-page":"S111","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"131","author":"Berek","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"J Immunol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int J Cancer"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2559.2002.01343.x","article-title":"Ki67 protein: the immaculate deception?","volume":"40","author":"Brown","year":"2002","journal-title":"Histopathology"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/1471-2407-11-486","article-title":"Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment","volume":"11","author":"Fasching","year":"2011","journal-title":"BMC Cancer"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13000-017-0608-5","article-title":"Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy","volume":"12","author":"Acs","year":"2017","journal-title":"Diagn Pathol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/jcp.26103","article-title":"Neoadjuvant chemotherapy in triple-negative breast cancer: a multicentric retrospective observational study in real-life setting","volume":"233","author":"Gamucci","year":"2018","journal-title":"J Cell Physiol"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12282-013-0474-2","article-title":"Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer","volume":"22","author":"Yoshioka","year":"2015","journal-title":"Breast Cancer"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:06:06Z","timestamp":1754161566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000706","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}